SGLT2 inhibitors have shown remarkablebenefits in slowing the progression of diabetic kidney disease [13], while GLP-1 RAs also offerrenal protection, though to a lesser extent [14]. This evidence concerns the gene GLP1R and diabetic kidney disease.